SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001558370-21-005321
Filing Date
2021-04-30
Accepted
2021-04-30 06:44:12
Documents
14
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A plx-20201231x10ka.htm   iXBRL 10-K/A 387238
2 EX-31.1 plx-20201231xex31d1.htm EX-31.1 14004
3 EX-31.2 plx-20201231xex31d2.htm EX-31.2 13819
  Complete submission text file 0001558370-21-005321.txt   627478

Data Files

Seq Description Document Type Size
4 EX-101.SCH plx-20201231.xsd EX-101.SCH 3010
5 EX-101.LAB plx-20201231_lab.xml EX-101.LAB 18955
6 EX-101.PRE plx-20201231_pre.xml EX-101.PRE 15580
7 EXTRACTED XBRL INSTANCE DOCUMENT plx-20201231x10ka_htm.xml XML 7875
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-33357 | Film No.: 21873659
SIC: 2836 Biological Products, (No Diagnostic Substances)